选择性PPAR δ激活和Seladelpar有效性在初级胆管胆结炎和超越
Alessio Gerussi1, Matteo Fornai2
1Centre for Autoimmune Liver Diseases, Division of Gastroenterology, Fondazione IRCCS San Gerardo dei Tintori, ERN-RARE LIVER Center, Monza, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Pharmacological research
|February 19, 2026
概括
塞拉德尔帕是一种PPAR-δ激动剂,已被批准用于初级胆道胆炎患者,初始治疗反应不足. 这次审查涵盖了PPAR-δ特性和Seladelpar.
科学领域:
- 药理学和胃肠病学 药理学和胃肠病学
- 胆固醇性肝脏疾病的分子机制
背景情况:
- 初级胆管胆炎 (PBC) 是一种罕见的胆固醇性肝病.
- 过氧体增殖器激活受体三角 (PPAR-δ) 是一种核受体.
- 选择性PPAR-δ激动剂为特定患者群体提供治疗方法.
研究的目的:
- 审查PPAR-δ的特征和组织活性.
- 总结一下Seladelpar的药理学,它是一种选择性的PPAR-δ激动剂.
- 为评估Seladelpar在PBC中的临床疗效和安全提供背景.
主要方法:
- 关于PPAR-δ生物学和功能的文献综述.
- Seladelpar. 的药理资料摘要
- 对PBC中的Seladelpar的临床前和临床数据的分析.
主要成果:
- 塞拉德尔帕可以选择性地激活PPAR-δ.
- PPAR-δ在多种组织中表现出多样化的活动.
- 临床数据支持Seladelpar在PBC中的疗效和安全性.
结论:
- 塞拉德尔帕是PBC患者的有价值的治疗选择.
- 了解PPAR-δ机制对于向治疗至关重要.
- 进一步的研究可能会阐明PPAR-δ激动剂的更广泛应用.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
563
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
563
01:28Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K